Valeant reiterated its intention to file it on or before April 29.
Stay here and make both call and put ending nothing
Rodman & Renshaw's Raghuram Selvaraju maintained a Buy rating on the company, with a price target of $105. Notice Of Default Selvaraju mentioned that the notice did not "accelerate any of Valeant's indebtedness, and under the covenants Valeant currently has in place with its creditors, the company has 60 days to cure the condition that led to the default notice, namely the delay in the filing of its 2015 Form 10-K." This means that the default situation would be rectified if the company filed its Form 10-K by June 11. Given that Valeant Pharma has repeatedly stated that it intends to file by the end of April, Selvaraju believes that "it is highly unlikely that this notice would lead to an actual default." The analyst also pointed out that Centerbridge was not in a position to force Valeant Pharma to agree to further concessions and that it would not be in Centerbridge's best interest to force an actual default. "Intriguing" Stock Selvaraju believes that the company continues to be an "intriguing" choice in the specialty pharma space, pointing out that companies in the industry have been facing huge pressure in recent months. "However, we maintain our view that Valeant, with its significantly greater diversification across both clinical indications and product types, along with its presence in medical devices and consumer health, is better positioned to weather market pressures than many of its more-specialized competitors," the analyst added. Acquire Media
That is the news out right now
Think this over, if not because of the delay of statement which raise the concern of default, how could you have had the chance buying a $100s stock at 30s? The default is not going to happen, shorting at this level means you are not going to live.
New to this stock, Bought at $28s yesterday, and sold at 31s.... and had to buy back at 32s to 33s after reading more about the news..... It would not stop till $50s.
For the patent issue, Guess that the patent would be break into a few parts eventually. Since Zhang has done a lots of work on CRISPY with many new discoveries such as how it works in cells. I would not worry at all about the patent compared to 150 billion future markets.